KURA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Caspian Therapeutics unveils KO-7246 at EASD as a potential best-in-class menin inhibitor for diabetesSep 29, 2026
- Kura Oncology announced a Blood publication highlighting ziftomenib’s differentiated binding profile and preclinical activityAug 10, 2026
- Kura Oncology and Kyowa Kirin reported encouraging long-term results for the ziftomenib and 7+3 combination in newly diagnosed AMLJun 11, 2026
- Kyowa Kirin and Kura Oncology started a Japanese Phase 2 registration-directed trial of Ziftomenib in relapsed or refractory NPM1-mutant AMLApr 24, 2026
- Kura Oncology reported strong activity of darlifarnib plus cabozantinib in previously treated renal cell carcinoma patientsApr 17, 2026